Therapy in neuromuscular disease

Neurologic Clinics

Volumn 19, Issue 1, 2001, Pages 205-215

  Younger, David S ^a   Raksadawan, Natte ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; IMMUNOGLOBULIN; METHOTREXATE; PREDNISONE;

ELECTROMYOGRAPHY; IMMUNOTHERAPY; MYASTHENIA GRAVIS; MYOPATHY; NEUROMUSCULAR DISEASE; PATHOGENESIS; POLYMYOSITIS; PRIORITY JOURNAL; REVIEW; THYMECTOMY; THYMUS;

EID: 0035015377     PISSN: 07338619     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8619(05)70013-X     Document Type: Article

References (70)

1. Relevance of experimental models of myasthenia gravis to human acquired myasthenia gravis
2. Limbic encephalitis and immunological perturbations in two patients with thymoma
3. Type 1 cryoglobulinemia associated with a thymic tumor: Successful treatment with plasma exchange
4. Giant cell myocarditis and myositis
5. Results of transcervical thymectomy for myasthenia gravis in 100 consecutive patients
6. Long-term maintenance ACTH therapy in myasthenia gravis
7. Aspects of the natural history of myasthenia gravis: Crisis and death
8. Immunosuppressive treatment. Their efficacy on myasthenia gravis patient's outcome and on the natural history of the disease
9. Clinical features, pathogenesis, diagnosis, and treatment of the inflammatory myopathies
10. Myasthenia gravis
11. Lambert lecture: Immunotherapy in neuromuscular disorders: Current and future strategies
12. Treatment of experimental myasthenia gravis with cyclosporine A
13. Combined ELS and MG
14. Effect of adrenocorticotropic hormone (ACTH) and cortisone administration in patients with myasthenia gravis
15. Pure red cell aplasia associated with malignant thymoma, myasthenia gravis, polyclonal large granular lymphocytosis and clonal thymic T cell expansion
16. Progress toward gene therapy of Duchenne muscular dystrophy
17. Myasthenia gravis: Stimulation of antireceptor autoantibodies by autoreactive T cell lines
18. Thymectomy for myasthenia gravis: Analysis of the controversies regarding technique and results
19. Myasthenia gravis: Recommendations for clinical research standards
20. "Maximal" thymectomy for myasthenia gravis: Results
21. "Maximal" thymectomy for myasthenia gravis: Surgical anatomy and operative technique
22. Treatment of myasthenia gravis with prednisone
23. Response to thymectomy in Chinese patients with myasthenia gravis
24. Post-thymectomy myasthenia gravis
25. Cellular and molecular mechanisms of cyclosporine nephrotoxicity
26. Experimental autoimmune myasthenia gravis: A model of myasthenia gravis in rats and guinea pigs
27. Myasthenia gravis with thymoma
28. Long-term administration of corticosteroids in myasthenia gravis
29. Thymectomy and malignancy
30. Immunosuppressive drugs: Azathioprine in the treatment of myasthenia gravis
31. Predictors of survival following surgical resection of thymoma
32. The thymus in myasthenia gravis: Changes typical for the human disease are absent in experimental autoimmune myasthenia gravis of the Lewis rat
33. The treatment of severe myasthenia gravis with immunosuppressive agents
34. Effects of immunosuppressive drugs (azathioprine)
35. Clinical evaluation of ACTH in myasthenia gravis
36. Thymectomy for myasthenia gravis: Recent observations and comparisons with past experience
37. The pathological basis of thymoma-associated myasthenia gravis
38. Bilineage hematopoietic inhibitor and T lymphocyte dysfunction in a patient with pure red blood cell aplasia, myasthenia gravis, and thymoma
39. Multidisciplinary integrated psychosocial and palliative care
40. Myasthenia gravis in patients with thymoma, with particular reference to onset after thymectomy
41. Overlap myasthenic syndrome: Combined myasthenia gravis and Eaton-Lambert syndrome
42. HLA antigens, autoantibody production, and associated diseases in thymoma patients with and without myasthenia gravis
43. Long-term corticosteroid treatment in myasthenia gravis: Report of 116 patients
44. Autoimmune response to acetylcholine receptor
45. Thymic abnormalities: Antigen or antibody? Response to thymectomy in myasthenia gravis
46. Association of neuromyotonia with peripheral neuropathy, myasthenia gravis and thymoma: A case report
47. Thymoma: Diagnosis and management
48. Effects of cyclosporine on human T cell activation
49. Cyclosporine A vs azathioprine in the treatment of myasthenia gravis: Final results of a randomized, controlled double-blind trial
50. Transplantation of myasthenia gravis thymus to SCID mice
51. Gradually increasing doses of prednisone in myasthenia gravis: Reducing the hazards of treatment
52. Effects of cortisone in certain neuromuscular disorders
53. Myasthenia gravis: Effect of treatment with anterior pituitary extract
54. Myasthenia gravis: A new hypothesis
55. The spectrum of diseases associated with thymoma
56. Steps in the generation of autoantibodies
57. A clinical therapeutic trial of cyclosporine in myasthenia gravis
58. Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis
59. Effects of adrenocorticotropic hormone on neuromuscular function in patients with myasthenia gravis
60. Effects of adrenocorticotropic hormone on neuromuscular function in patients with myasthenia gravis
61. Myasthenia gravis and invasive thymoma: A 20-year experience
62. On classification, natural history and treatment of the myopathies
63. Malignant thymoma
64. Benefit from alternate day prednisone in myasthenia gravis
65. Pathologisch-anatomischer beitrag zur Erb'schen krancheit (myasthenia gravis)
66. Neuromuscular disorders and thymoma
67. Maximum thymectomy for myasthenia gravis
68. Myasthenia gravis: Historical perspectives and overview
69. Overview of motor disorders